All In Biotech

Drug Trial Radar · NCT06345716

Paracetamol-Tramadol and Paracetamol-caffeine Versus Placebo in the Emergency Discharge Treatment of Renal Colic

Last checked: Nov 19, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 1,500 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

1,500

Planned (sponsor's estimate)

Start

Apr 10, 2024

Primary completion

Mar 15, 2025

Study completion Nov 30, 2025

Sponsor

Lead sponsor
University of MonastirAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 3, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, randomized, single-blind study. Patients included in the study after successful treatment of the acute attack were randomized upon discharge from the Emergency Department into three groups: oral paracetamol-tramadol group, oral paracetamol-caffeine group and oral placebo group.

Conditions

  • Renal Colic

Interventions

  • paracétamol tramadolDrug

    Each patient received 1 tablet \* 2/day synalvic (325 mg of paracetamol + 37.5 mg of tramadol) for 7 days

  • Paracétamol cafeineDrug

    Each patient received 1 tab \* 3/d stopalgic extra (65mgcaffeine+500mg paracetamol) for 7 days

  • PlaceboDrug

    Each patient received 1 tab \* 3 / d of placebo (flour) every day for 7 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recurrence of RC and ED readmissionTime frame: 7 day after inclusion

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Semir Nouira

    Monastir, Tunisia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.